IDLDX.ST Neovici Holding AB (publ)
- Market cap
- SEK 76.0M
- P/E
- -
- P/B
- 0.55x
- ROE
- 0.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is IDLDX.ST undervalued?
Graham numberThe Graham number of Neovici Holding AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Neovici Holding AB (publ) fundamental analysis
No fundamental analysis for Neovici Holding AB (publ) yet.
Neovici Holding AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Neovici Holding AB (publ)
IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. Its vitro diagnostic biomarkers are used in breast, bladder, and prostate cancer therapies. The company was formerly known …
Full company profileNeovici Holding AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Neovici Holding AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 54.6K | 502K | 782K | 443K | 84.0K | 12.0M | 37.0M | 43.0M | 57.4M | 53.1M | 62.6M |
| Gross Profit | 54.6K | 226K | -470K | 70.5K | 63.0K | -5.05M | -2.11M | -2.10M | 11.7M | 27.7M | 39.4M |
| Operating Income | -9.23M | -17.3M | -20.8M | -20.7M | -24.1M | -50.6M | -59.3M | -59.8M | -43.4M | -10.7M | 74.0K |
| EBITDA | -9.22M | -15.0M | -16.5M | -16.2M | -19.5M | -30.3M | -12.1M | -13.8M | -37.5M | -8.07M | 2.17M |
| Net Income | -9.23M | -17.3M | -20.8M | -16.2M | -19.5M | -50.0M | -59.0M | -59.3M | -42.4M | -12.2M | 270K |
| EPS | -0.31 | -0.58 | -0.51 | -0.40 | -0.26 | -0.52 | -0.27 | -0.26 | -0.18 | -0.05 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 66.4M | 49.5M | 57.4M | 91.4M | 60.5M | 227M | 236M | 175M | 134M | 177M | 175M |
| Total Liabilities | 2.97M | 2.84M | 2.90M | 11.0M | 4.22M | 9.96M | 13.3M | 11.2M | 12.9M | 28.7M | 26.7M |
| Shareholders' Equity | 63.5M | 46.7M | 54.5M | 80.4M | 56.3M | 214M | 223M | 164M | 121M | 148M | 148M |
| Cash & Short-term Investments | 32.9M | 17.2M | 29.7M | 13.6M | 42.0M | 18.4M | 65.2M | 50.7M | 47.8M | 36.6M | 35.3M |
| Total Debt | - | - | - | - | - | - | - | - | - | 13.2M | 12.2M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -7.17M | -15.2M | -16.4M | -15.1M | -18.9M | -28.2M | -13.7M | -13.4M | -2.36M | -7.60M | 1.40M |
| Capital Expenditure | 9.68M | 318K | 0.00 | 245K | 53.0K | 370K | 4.06M | 498K | 581K | 1.55M | 0.00 |
| Free Cash Flow | -16.8M | -15.6M | -16.4M | -15.3M | -19.0M | -28.6M | -17.8M | -14.7M | -2.36M | -9.15M | 1.40M |
| Ratios | |||||||||||
| ROE | -14.6% | -37.0% | -38.1% | -20.2% | -34.6% | -23.4% | -26.5% | -36.2% | -35.0% | -8.2% | 0.2% |
| ROA | -13.9% | -34.9% | -36.2% | -17.7% | -32.2% | -22.0% | -25.0% | -33.9% | -31.6% | -6.9% | 0.2% |
| Net Profit Margin | -16,912.0% | -3,440.2% | -2,654.9% | -3,659.8% | -23,165.5% | -417.0% | -159.4% | -137.8% | -73.9% | -22.9% | 0.4% |
| Debt to Equity | - | - | - | - | - | - | - | - | - | 0.09x | 0.08x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Neovici Holding AB (publ) dividends
Neovici Holding AB (publ) has not paid dividends in the last 9 fiscal years.
Who owns Neovici Holding AB (publ)
- Insiders 31.15%
- Institutions 13.01%
- Public & others 55.84%
- Shares outstanding 230M
- Free float 114M
Neovici Holding AB (publ) company profile
- Company name
- Neovici Holding AB (publ)
- Ticker
- IDLDX.ST
- ISIN
- SE0003883990
- Exchange
- Stockholm Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 25
- Fiscal year end
- December
- Address
- KarlsbodavAegen 39, Stockholm, Sweden, 168 67
- Phone
- 46 87 99 67 50
- Website
- idldiagnostics.com
About Neovici Holding AB (publ)
IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. Its vitro diagnostic biomarkers are used in breast, bladder, and prostate cancer therapies. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) in May 2025. IDL Diagnostics AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Neovici Holding AB (publ) management
6- Mr. Gustav StenChief Executive Officer
- Ms. Ellen DittbernerChief Finance Officer
- Ms. Maria SundbergChief Operations Officer
- Ms. Leyla Ali DholeyChief Scientific Officer
- Erika NemetiCommunications & IR Director
- Ms. Jocelyn AkerbergChief Quality Officer